These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 31492858

  • 1. Mitigation of off-target toxicity in CRISPR-Cas9 screens for essential non-coding elements.
    Tycko J, Wainberg M, Marinov GK, Ursu O, Hess GT, Ego BK, Aradhana, Li A, Truong A, Trevino AE, Spees K, Yao D, Kaplow IM, Greenside PG, Morgens DW, Phanstiel DH, Snyder MP, Bintu L, Greenleaf WJ, Kundaje A, Bassik MC.
    Nat Commun; 2019 Sep 06; 10(1):4063. PubMed ID: 31492858
    [Abstract] [Full Text] [Related]

  • 2. SliceIt: A genome-wide resource and visualization tool to design CRISPR/Cas9 screens for editing protein-RNA interaction sites in the human genome.
    Vemuri S, Srivastava R, Mir Q, Hashemikhabir S, Dong XC, Janga SC.
    Methods; 2020 Jun 01; 178():104-113. PubMed ID: 31494246
    [Abstract] [Full Text] [Related]

  • 3. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
    Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA.
    Nat Methods; 2015 Dec 01; 12(12):1143-9. PubMed ID: 26501517
    [Abstract] [Full Text] [Related]

  • 4. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
    Klann TS, Black JB, Chellappan M, Safi A, Song L, Hilton IB, Crawford GE, Reddy TE, Gersbach CA.
    Nat Biotechnol; 2017 Jun 01; 35(6):561-568. PubMed ID: 28369033
    [Abstract] [Full Text] [Related]

  • 5. CRISPR-Cas9 screens reveal common essential miRNAs in human cancer cell lines.
    Merk DJ, Paul L, Tsiami F, Hohenthanner H, Kouchesfahani GM, Haeusser LA, Walter B, Brown A, Persky NS, Root DE, Tabatabai G.
    Genome Med; 2024 Jun 17; 16(1):82. PubMed ID: 38886809
    [Abstract] [Full Text] [Related]

  • 6. Prediction of CRISPR sgRNA Activity Using a Deep Convolutional Neural Network.
    Xue L, Tang B, Chen W, Luo J.
    J Chem Inf Model; 2019 Jan 28; 59(1):615-624. PubMed ID: 30485088
    [Abstract] [Full Text] [Related]

  • 7. CSC software corrects off-target mediated gRNA depletion in CRISPR-Cas9 essentiality screens.
    Perez AR, Sala L, Perez RK, Vidigal JA.
    Nat Commun; 2021 Nov 09; 12(1):6461. PubMed ID: 34753924
    [Abstract] [Full Text] [Related]

  • 8. Highly Parallel Profiling of Cas9 Variant Specificity.
    Schmid-Burgk JL, Gao L, Li D, Gardner Z, Strecker J, Lash B, Zhang F.
    Mol Cell; 2020 May 21; 78(4):794-800.e8. PubMed ID: 32187529
    [Abstract] [Full Text] [Related]

  • 9. Genome-scale CRISPR pooled screens.
    Sanjana NE.
    Anal Biochem; 2017 Sep 01; 532():95-99. PubMed ID: 27261176
    [Abstract] [Full Text] [Related]

  • 10. CRISPcut: A novel tool for designing optimal sgRNAs for CRISPR/Cas9 based experiments in human cells.
    Dhanjal JK, Radhakrishnan N, Sundar D.
    Genomics; 2019 Jul 01; 111(4):560-566. PubMed ID: 29605634
    [Abstract] [Full Text] [Related]

  • 11. Whole genome analysis of CRISPR Cas9 sgRNA off-target homologies via an efficient computational algorithm.
    Zhou H, Zhou M, Li D, Manthey J, Lioutikova E, Wang H, Zeng X.
    BMC Genomics; 2017 Nov 17; 18(Suppl 9):826. PubMed ID: 29219081
    [Abstract] [Full Text] [Related]

  • 12. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V, Josipović G, Zoldoš V, Vojta A.
    Methods; 2019 Jul 15; 164-165():109-119. PubMed ID: 31071448
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing.
    Klann TS, Crawford GE, Reddy TE, Gersbach CA.
    Methods Mol Biol; 2018 Jul 15; 1767():447-480. PubMed ID: 29524151
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CRISPR-Mediated Transcriptional Repression in Toxoplasma gondii.
    Markus BM, Boydston EA, Lourido S.
    mSphere; 2021 Oct 27; 6(5):e0047421. PubMed ID: 34643425
    [Abstract] [Full Text] [Related]

  • 20. Potential pitfalls of CRISPR/Cas9-mediated genome editing.
    Peng R, Lin G, Li J.
    FEBS J; 2016 Apr 27; 283(7):1218-31. PubMed ID: 26535798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.